Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $40.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 226.53% from the stock’s current price.
A number of other equities analysts also recently commented on the company. Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $40.33.
Get Our Latest Research Report on OMER
Omeros Stock Down 7.8%
Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. The firm had revenue of $9.89 million for the quarter, compared to the consensus estimate of $4.19 million. As a group, analysts anticipate that Omeros will post -1.54 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in Omeros in the first quarter valued at about $357,000. XTX Topco Ltd bought a new position in Omeros in the second quarter valued at about $191,000. Invesco Ltd. lifted its holdings in Omeros by 34.1% in the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after acquiring an additional 29,644 shares during the period. Marshall Wace LLP lifted its holdings in Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after acquiring an additional 97,224 shares during the period. Finally, Sei Investments Co. bought a new position in Omeros in the second quarter valued at about $40,000. 48.79% of the stock is owned by institutional investors.
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Read More
- Five stocks we like better than Omeros
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
